Bausch Health(BHC)

Focus: Bausch Health is a Quebec-headquartered public pharmaceutical company with $8.8B in FY2025 revenue, operating across immunology, gastroenterology, neurology, cardiovascular, and infectious diseases. The company is heavily concentrated on small-molecule therapeutics with critical dependence on legacy and near-LOE assets.

Immunology Gastroenterology Neurology Cardiovascular

Profile data last refreshed 10h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Bausch Health

AI assessmentNot Hiring

No open roles listed right now. Follow Bausch Health to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

6/9 — Partial

Company HealthSolid

Pipeline

Early-stage

50 total

LOE Risk

1 imminent

OSMOPREP

Hiring

Stable

Revenue

$8.8B

FY2025

Key Products

XIFAXAN

Infectious Diseases / Gastroenterology

$1.1B Part D

LOE Approaching

Dominant cash cow representing 100% of company revenue; loss of exclusivity will force portfolio-wide contraction without pipeline offsets.

Help build intelligence for Bausch Health

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Access to a $8.8B revenue base with exposure to multiple therapeutic areas and a diversified product portfolio spanning immunology, GI, neurology, and cardiovascular segments.
Opportunity to work on a deep pipeline of 30 programs spanning Phase 1–4, including emerging assets in obesity (naltrexone/bupropion), pancreatic cancer (methylnaltrexone), and dermatology (IDP series).
Presence of marketed franchises with extension potential, particularly rifaximin (XIFAXAN) in diarrhea indications and psoriasis/atopic dermatitis platforms (brodalumab, IDP-118, IDP-122, IDP-124).

Watch Out For

Dangerous revenue cliff: 100% of revenue concentration in XIFAXAN with LOE approaching — company faces immediate revenue erosion with minimal near-term replacement revenue from pipeline.
Historically unprofitable: FY2025 net loss of $592M and FY2024 loss of $225M signal structural challenges; low R&D intensity (7%) relative to revenue suggests limited reinvestment in innovation.
Zero active job openings and minimal hiring visibility suggest organizational contraction or hiring freeze, despite financial volatility and patent cliff exposure.

Generated by Claude from Bausch Health's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

EQUETRO

Neurology

$1M Part D

LOE Approaching

Minimal revenue contributor with LOE risk; demonstrates portfolio dependency on aging assets.

LASIX

Cardiovascular

$610K Part D

LOE Approaching

Legacy diuretic with negligible revenue; positioned as portfolio breadth rather than growth driver.

MOVIPREP

Gastroenterology

$73K Part D

LOE Approaching

Bowel preparation agent with minimal revenue and approaching LOE; limited commercial significance.

DIURIL

Cardiovascular

$18K Part D

LOE Approaching

Iconic but declining antihypertensive with negligible modern revenue; legacy portfolio filler.

LOTENSIN HCT

Hypertension

$10K Part D

LOE Approaching

Combination antihypertensive with minimal revenue; approaching LOE with no replacement identified.

MILPREM-200

Psychiatry / Women's Health

Pre-Launch

Pre-launch combination therapy; timeline and commercial viability remain uncertain.

COLONAID

Gastroenterology

Post-LOE

Post-LOE ANDA product with minimal revenue potential; represents portfolio legacy rather than growth.

MILTOWN

Anxiety Disorders

LOE Approaching

Vintage anxiolytic approaching LOE with minimal modern relevance; historical asset only.

RELISTOR

Opioid-Induced Constipation

Peak4.4yr

Only asset explicitly at peak lifecycle with 2030 LOE date; reasonable bridge asset but insufficient to offset XIFAXAN cliff.

Pipeline & Clinical Trials

B&L RD2135-01 lens C

Myopia

N/A

Clinical Trials (1)

NCT01583868A Study to Evaluate the Product Feasibility of Two New Silicone Hydrogel Contact Lenses

N/A

Senofilcon C

Myopia

N/A

Clinical Trials (1)

NCT03351101Clinical Study of Approved Contact Lenses

N/A

Redesigned Purevision Contact Lens

Myopia

N/A

Clinical Trials (1)

NCT01118338Evaluation of Two Different Designs of Bausch & Lomb Contact Lenses

N/A

Technolas® TENEO 317 Model 2

Myopia

N/A

Clinical Trials (1)

NCT04111757A Study With Technolas® TENEO 317 Model 2 Excimer Laser to Treat Participants With Myopia or Myopic Astigmatism

N/A

BL-300-PFM04

Contact Lens Wear

N/A

Clinical Trials (1)

NCT04175340A Safety and Effectiveness Study of a New Preservative Free Rewetting Drop

N/A

ZenLens™

Keratoconus

N/A

Clinical Trials (1)

NCT03249233Corneal Thickness Changes With Scleral Contact Lenses

N/A

salix probiotic blend

Functional Gastrointestinal Disorders

N/A

Clinical Trials (1)

NCT04155801A Study to Assess the Efficacy and Safety of Salix Probiotic Blend in Participants With Functional Gastrointestinal Disturbances

N/A

REVIVE samfilcon B custom toric contact lenses

Astigmatism

N/A

Clinical Trials (1)

NCT06785194Revive Toric RWE Study

N/A

kalifilcon A lenses

Habitual Soft Contact Lens Use

N/A

Clinical Trials (1)

NCT04555031Evaluation of Surface Refractive Index Shift of Kalifilcon A Lenses Compared to Dailies Total 1, Precision 1 and Biotrue ONEday Lenses

N/A

Artelac Rebalance

Dry Eye

N/A

Clinical Trials (1)

NCT01791426A Study to Evaluate the Performance and Safety of Artelac Rebalance® Versus Vismed in the Management of Dry Eye

N/A

LD127025 MF

Presbyopia

N/A

Clinical Trials (1)

NCT01959178A Study to Evaluate a Mid Add Multi-Focal Soft Contact Lens

N/A

Bausch & Lomb Multi-Purpose Solution

Contact Lens Solutions

N/A

Clinical Trials (1)

NCT00710879Evaluation of a Multi-Purpose Solution

N/A

dihydroergotamine mesylate

Migraine

N/A

Clinical Trials (1)

NCT00203268A Study Examining the Use of a Migraine Medicine in the Treatment of Two Migraine Attacks in Patients Who Have Increased Skin Sensitivity

N/A

BCMC lens

Myopia

N/A

Clinical Trials (1)

NCT07511387Efficacy of a Novel Myopia Defocus Spectacle Lens in School-Aged Children

N/A

Methylnaltrexone

Opioid-induced Constipation

N/A

Clinical Trials (1)

NCT01368562Compassionate Use Study of Methylnaltrexone

N/A

clindamycin phosphate/adapalene/benzoyl peroxide

Acne Vulgaris

N/A

imiquimod

Mycosis Fungoides

N/A

Clinical Trials (2)

NCT03914417Genomic Markers Before and After Treatment of Actinic Keratosis With Imiquimod 3.75% Cream

Phase 2

NCT02301494Effectiveness of Imiquimod Topical Cream in Early Stage Cutaneous T-cell Lymphoma

N/A

new silicone hydrogel daily disposable multifocal contact lens, the Bausch + Lomb

Myopia and Hyperopia and Presbyopia

N/A

Clinical Trials (1)

NCT05660577Evaluation of Product Performance of a New Silicone Hydrogel Multifocal Contact Lens

N/A

samfilcon A Lenses with EPG01 Packaging Solution

Contact Lens Wearer

N/A

Clinical Trials (1)

NCT051269532-Hour Dispensing Evaluation of Samfilcon A Lenses With EPG01 Packaging Solution Compared to Commercially Available B+L Ultra Lenses

N/A

Evaluation of the Bausch & Lomb PureVision Under Nighttime Driving Conditions

Astigmatism

N/A

Clinical Trials (1)

NCT00581659Evaluation of the Bausch & Lomb PureVision Under Nighttime Driving Conditions

N/A

Comparing Two Different Ways to Take MoviPrep® Before Colonoscopy

Colonoscopy

N/A

Clinical Trials (1)

NCT00929916Comparing Two Different Ways to Take MoviPrep® Before Colonoscopy

N/A

IC-8 Apthera IOL New Enrollment Post Approval Study

Cataract

N/A

Clinical Trials (1)

NCT06060041IC-8 Apthera IOL New Enrollment Post Approval Study

N/A

pergolide

Parkinson Disease

N/A

Clinical Trials (1)

NCT00624741Compassionate Use Study of Pergolide in Patients With Parkinson's Disease

N/A

Bausch & Lomb contact lens

Myopia

N/A

Clinical Trials (1)

NCT01130974A Study to Assess the Safety and Efficacy of a Daily Disposable Contact Lens

N/A

Administration of Lotemax

Sjogren's Disease

N/A

Clinical Trials (1)

NCT02322528Evaluation of Ocular Surface Inflammatory Mediators Effected by Lotemax

N/A

B&L Investigational Contact Lens

Myopia

N/A

Clinical Trials (1)

NCT01449526A Study to Evaluate the Safety and Efficacy of a New Silicone Hydrogel Contact Lens Design

N/A

PEG-SD

Hyponatremia

N/A

Clinical Trials (1)

NCT01299779Incidence of Hyponatremia in PEG-SD Compared to PEG-ELS

N/A

Dental exam and periodontal cleaning if needed

Cirrhosis

N/A

Clinical Trials (1)

NCT06052150Oral Health In Cirrhosis of the Liver (ORACLE)

N/A

Efudex

Photo-aging

N/A

Clinical Trials (1)

NCT00121511The Effect of Efudex Treatment on Photoaged Skin

N/A

Retisert

Uveitis, Posterior

N/A

Clinical Trials (1)

NCT03145025Corneal Endothelial Cell Density in Eyes Treated With a Fluocinolone Acetonide Intravitreal Implant

N/A

A Patient Reported Ocular Comfort Assessment Comparing Bepreve to Lastacaft

Allergic Conjunctivitis

N/A

Clinical Trials (1)

NCT01339507A Patient Reported Ocular Comfort Assessment Comparing Bepreve to Lastacaft

N/A

ISTA Tears

Dry Eye Disease

N/A

Clinical Trials (1)

NCT01650584Evaluation of Ocular Comfort With ISTA Tears vs Systane

N/A

corneas assigned by donor age group

Corneal Disease

N/A

Clinical Trials (1)

NCT00006411Cornea Donor Study

N/A

Prolensa

Cataract

N/A

Clinical Trials (1)

NCT01847638Prolensa (Bromfenac) 0.07% QD vs. Ilevro (Nepafenac) 0.3% QD for Treatment of Ocular Inflammation Post Cataract Surgery

N/A

Xiidra

Glaucoma

N/A

Thermage FLX

Facial Skin Laxity

N/A

Clinical Trials (1)

NCT03894371Thermage FLX System to Treat the Face, Neck, and Eyelids

N/A

No Intervention

Neovascular Age-Related Macular Degeneration

N/A

Clinical Trials (1)

NCT02367365Neovascular Morphology and Persistent Disease Activity Among Patients With NV AMD

N/A

ABT12 Multi-Purpose Solution

Contact Lens Wear

N/A

Clinical Trials (1)

NCT03897751A Safety and Effectiveness Study of BL-ABT12 Multi-Purpose Solution for Use by Participants With Soft Contact Lenses

N/A

Fluocinolone Acetonide 0.59 mg

Inflammation

N/A

Clinical Trials (1)

NCT01060787Evaluation of Corneal Endothelial Cell Density in Subjects Who Have Had a Fluocinolone Acetonide Implant

N/A

clindamycin phosphate, adapalene and benzoyl peroxide

Acne Vulgaris

N/A

Clinical Trials (1)

NCT07205107Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Triple Combination Gel in Canadian Patients With Acne Vulgaris

N/A

No Intervention

Neovascular Age-related Macular Degeneration

N/A

Clinical Trials (1)

NCT02452840Photodynamic Therapy for PDA in NV AMD

N/A

Bausch & Lomb Multipurpose Solution - Rub Care

Contact Lens Solutions

N/A

Clinical Trials (1)

NCT00636363Safety and Efficacy of a Bausch & Lomb Multipurpose Solution When Compared to Ciba Vision Aquify Multipurpose Solution

N/A

Fipamezole ODT

Parkinson's Disease

N/A

Clinical Trials (1)

NCT01140841A Study of Safety and Tolerability of Fipamezole in Adult Subjects With Parkinson's Disease Who Are Receiving Levodopa

N/A

Fraxel® FTX Laser System

Skin Resurfacing

N/A

Clinical Trials (1)

NCT07214272A Phase 4 Clinical Study to Investigate the Effectiveness and Safety of Skin Resurfacing

N/A

Once a day Trientine

Wilson Disease

N/A

Clinical Trials (1)

NCT01472874Single Daily Dosage of Trientine for Maintenance Treatment for Wilson Disease

N/A

Aflibercept

Neovascular Age-related Macular Degeneration

N/A

Clinical Trials (1)

NCT02457026Adjunctive Photodynamic Therapy + Aflibercept vs. Afilbercept Alone for PDA in NV AMD

N/A

Pimecrolimus

Atopic Dermatitis

N/A

Clinical Trials (1)

NCT0056899710 Year Registry of Children (Ages 2-17 Years) With Eczema That Have Used Pimecrolimus

N/A

Fipamezole ODT

Parkinson's Disease

N/A

Clinical Trials (1)

NCT01149811A Study Comparing the Safety and Tolerability of Two Doses of Fipamezole in Adult Patients With Parkinson's Disease

N/A

REVIVE Contact Lens

Refractive Ametropia

N/A

Clinical Trials (1)

NCT060537361-Week Dispensing Evaluation of REVIVE™ Toric Soft Contact Lenses

N/A

enVista MX60E

Cataract

N/A

Clinical Trials (1)

NCT03603600Evaluate the Safety and Effectiveness of the enVista® One-Piece Hydrophobic Acrylic Trifocal Intraocular Lens

N/A

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 49 approved products, 149 clinical trials

Top TAs: Ophthalmology, Immunology, Gastroenterology

Publications: 25 in PubMed

SEC Filings: 2 available

Portfolio Health

Pre-Launch18 (37%)

Peak2 (4%)

LOE Approaching23 (47%)

Post-LOE6 (12%)

49 total products

Therapeutic Area Focus

Ophthalmology

153 pipeline

Immunology

3 marketed44 pipeline

Gastroenterology

7 marketed38 pipeline

Infectious Diseases

5 marketed18 pipeline

Cardiovascular

Financials (FY2025)

Revenue

$8.8B8%

R&D Spend

$604M(7%)14%

Net Income

-$592M

Hiring Trend

Stable

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles

Research Publications(10)

Recent peer-reviewed publications with author affiliations at this company

Canadian Treat-to-Target Practice Survey of Real-World Interventions and Strategies in Psoriasis (CAN TARGET PSORIASIS).

Dermatology and therapy

2026

PMID:41989658

A Review of Post-Inflammatory Pigmentation Changes: Pathophysiology, Diagnosis and Treatment.

CLINICAL PHARMACOLOGY Bumex is a loop diuretic with a rapid onset and short duration of action. Pharmacological and clinical studies have shown that 1 mg Bumex has a diuretic potency equivalent to approximately 40 mg furosemide. The major site of Bumex action is the ascending limb of the loop of Henle. The mode of action has been determined through various clearance studies in both humans and experimental animals. Bumex inhibits sodium reabsorption in the ascending limb of the loop of Henle, as shown by marked reduction of free-water clearance (CH 2 O) during hydration and tubular free-water reabsorption (T H 2 O) during hydropenia. Reabsorption of chloride in the ascending limb is also blocked by Bumex, and Bumex is somewhat more chloruretic than natriuretic. Potassium excretion is also increased by Bumex, in a dose-related fashion. Bumex may have an additional action in the proximal tubule. Since phosphate reabsorption takes place largely in the proximal tubule, phosphaturia during Bumex induced diuresis is indicative of this additional action. This is further supported by the reduction in the renal clearance of Bumex by probenecid, associated with diminution in the natriuretic response. This proximal tubular activity does not seem to be related to an inhibition of carbonic anhydrase. Bumex does not appear to have a noticeable action on the distal tubule. Bumex decreases uric acid excretion and increases serum uric acid. Following oral administration of Bumex the onset of diuresis occurs in 30 to 60 minutes. Peak activity is reached between 1 and 2 hours. At usual doses (1 mg to 2 mg) diuresis is largely complete within 4 hours; with higher doses, the diuretic action lasts for 4 to 6 hours. Diuresis starts within minutes following an intravenous injection and reaches maximum levels within 15 to 30 minutes. Several pharmacokinetic studies have shown that bumetanide, administered orally or parenterally, is eliminated rapidly in humans, with a half-life of between 1 and 1½ hours. Plasma protein-binding is in the range of 94% to 96%. Oral administration of carbon-14 labeled Bumex to human volunteers revealed that 81% of the administered radioactivity was excreted in the urine, 45% of it as unchanged drug. Urinary and biliary metabolites identified in this study were formed by oxidation of the N-butyl side chain. Biliary excretion of Bumex amounted to only 2% of the administered dose. Pediatric Pharmacology Elimination of bumetanide appears to be considerably slower in neonatal patients compared with adults, possibly because of immature renal and hepatobiliary function in this population. Small pharmacokinetic studies of intravenous bumetanide in preterm and full-term neonates with respiratory disorders have reported an apparent half-life of approximately 6 hours, with a range up to 15 hours and a serum clearance ranging from 0.2 mL/min/kg to 1.1 mL/min/kg. In a population of neonates receiving bumetanide for volume overload, mean serum clearance ra

10 marketed10 pipeline

Neurology

9 marketed9 pipeline

Oncology

9 marketed4 pipeline

Metabolic Diseases

6 marketed6 pipeline

Journal of cutaneous medicine and surgery

Showing 5 of 10 publications

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Bausch Health(BHC)

About Bausch Health

Why Work Here

Key Products

Watch Out For

Products & Portfolio (10)

Key Products by Revenue

Other Products (6)

Pipeline & Clinical Trials

Recent News · Bausch Health(10)

Open Jobs (0)

Financials (FY2025)

Hiring Trend

Research Publications(10)